Literature DB >> 16356093

Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.

Mirna Abraham-Nordling1, Ove Törring, Bertil Hamberger, Göran Lundell, Leif Tallstedt, Jan Calissendorff, Göran Wallin.   

Abstract

The effects of treatment modality for Graves' disease (GD) were studied with respect to long-term quality of life and present health status. A total of 179 patients with GD were randomized during the period 1983-1990 for treatment with antithyroid drugs, radioiodine, or surgery. A 36-item Short Form Health Status Survey questionnaire and specific questions for GD were sent to patients 14-21 years after randomization. Present medical records, and clinical and laboratory status were recorded. No major significant differences in quality of life among the three treatments were observed. Compared to a large Swedish reference group, all treatment groups had significantly lower scores for vitality (p < 0.05). The Mental Component Summary was lower for both the young medical, young surgical, and the older medical group (p < 0.05). Radioiodine-treated patients had a lower General Health score. Young medical patients (<35 years) had lower Mental Health scores (p < 0.05). There was also a strong trend, which barely met statistically significance, for older surgical and radioiodine groups for lower Mental Component Summary. GD patients have, compared with a large Swedish reference population, diminished vital and mental quality of life aspects even many years after treatment. The quality-of-life scores were not different among the three treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356093     DOI: 10.1089/thy.2005.15.1279

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  30 in total

1.  Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.

Authors:  Vishnu Sundaresh; Juan P Brito; Prabin Thapa; Rebecca S Bahn; Marius N Stan
Journal:  Thyroid       Date:  2017-02-06       Impact factor: 6.568

Review 2.  Hyperthyroidism (primary).

Authors:  Birte Nygaard
Journal:  BMJ Clin Evid       Date:  2010-07-19

3.  Reflections on the Management of Graves' Hyperthyroidism.

Authors:  Chantal Daumerie; Jacques Orgiazzi
Journal:  Eur Thyroid J       Date:  2018-07-19

4.  Current concepts in graves' disease.

Authors:  Christian M Girgis; Bernard L Champion; Jack R Wall
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

5.  A Prospective Comparative Study on Improvement of Hyperthyroid Cardiovascular Dysfunction in Patients Undergoing Total Thyroidectomy Versus Medical Management.

Authors:  S Muthukumar; K Ravikumar; S Dhalapathy; T Gomathy; S Umadevi; D Maruthupandian
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

Review 6.  Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.

Authors:  Vishnu Sundaresh; Juan P Brito; Zhen Wang; Larry J Prokop; Marius N Stan; Mohammad H Murad; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-07-03       Impact factor: 5.958

7.  Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination.

Authors:  Torquil Watt; Jakob Bue Bjorner; Mogens Groenvold; Ase Krogh Rasmussen; Steen Joop Bonnema; Laszlo Hegedüs; Ulla Feldt-Rasmussen
Journal:  Qual Life Res       Date:  2009-03-14       Impact factor: 4.147

8.  Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.

Authors:  Xiaomei Liu; Hui Guo; Juan Liu; Bingyin Shi
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

9.  Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing.

Authors:  Torquil Watt; Ase Krogh Rasmussen; Mogens Groenvold; Jakob Bue Bjorner; Sara Hope Watt; Steen Joop Bonnema; Laszlo Hegedüs; Ulla Feldt-Rasmussen
Journal:  Qual Life Res       Date:  2008-06-27       Impact factor: 4.147

Review 10.  Hyperthyroidism (primary).

Authors:  Birte Nygaard
Journal:  BMJ Clin Evid       Date:  2008-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.